Verastem Files for Orphan Disease Status in US and EU for VS-6063 in Mesothelioma
Verastem (NASDAQ: VSTM) announced the filing of
orphan drug designation for VS-6063.
Verastem is seeking orphan drug designation in the US and the EU for the
use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a
potentially pivotal study in mesothelioma midyear 2013.
Orphan designation grants US market exclusivity to a drug for the
treatment of a specified condition for a period of seven years following
FDA marketing approval and 10 years of market exclusivity in member
states of the EU if received. Additional potential benefits of orphan